Pre-Market Top Loser: GNCA stock at $0.0001 on NASDAQ, Chapter 11 fallout to watch

GNCA stock plunged to $0.0001 in pre-market trading on 19 Mar 2026, marking one of the session’s biggest declines. Genocea Biosciences, Inc. (GNCA) traded just 30,268 shares versus an average of 80,568, reflecting thin liquidity and heavy selling pressure. The Nasdaq-listed biotechnology firm still shows legacy Chapter 11 restructuring on its record, so price moves reflect corporate distress and illiquid trading rather than fresh clinical wins. Traders should note the wide gap between the 50-day average $0.00472 and today’s price when sizing positions.